AnaptysBio (ANAB) Financials

$24.69 +0.14 (+0.57%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$26.40 +1.71 (+6.93%)

As of 04:05 AM Eastern

Annual Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-5.41	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Consolidated Net Income / (Loss)	-5.41	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Net Income / (Loss) Continuing Operations	-5.41	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Total Pre-Tax Income	-5.27	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Total Operating Income	-3.32	-3.03	-29	-67	-107	-24	-57	-115	-164	-115
Total Gross Profit	18	17	10	5.00	8.00	75	63	10	17	91
Total Revenue	18	17	10	5.00	8.00	75	63	10	17	91
Operating Revenue	18	17	10	5.00	8.00	75	63	10	17	91
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	21	20	39	72	115	99	120	125	182	206
Selling, General & Admin Expense	3.59	4.29	9.34	16	16	19	21	37	42	42
Research & Development Expense	17	15	29	56	99	80	98	89	140	164
Total Other Income / (Expense), net	-1.94	-1.23	-1.29	4.87	9.94	3.95	-0.98	-14	0.79	-30
Interest Expense	0.46	0.46	1.78	1.65	1.04	0.00	1.45	21	18	50
Interest & Investment Income	0.02	0.13	1.62	6.69	11	3.96	0.43	7.55	19	20
Other Income / (Expense), net	-1.50	-0.90	-1.14	-0.16	0.00	-0.01	0.04	0.01	-0.00	0.01
Income Tax Expense	0.14	0.00	0.00	-0.19	-0.15	0.00	0.00	0.02	-0.00	0.00
Basic Earnings per Share	($2.12)	($1.62)	($1.52)	($2.50)	($3.60)	($0.73)	($2.11)	($4.57)	($6.08)	($5.12)
Weighted Average Basic Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.30M	27.43M	28.17M	26.92M	28.38M
Diluted Earnings per Share	($2.12)	($1.62)	($1.52)	($2.50)	($3.60)	($0.73)	($2.11)	($4.57)	($6.08)	($5.12)
Weighted Average Diluted Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.30M	27.43M	28.17M	26.92M	28.38M
Weighted Average Basic & Diluted Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.30M	27.67M	27.93M	26.76M	30.67M

This table shows AnaptysBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Consolidated Net Income / (Loss)	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Net Income / (Loss) Continuing Operations	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Total Pre-Tax Income	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Total Operating Income	-30	-26	-44	-40	-38	-42	-42	-40	-23	-9.67	-28
Total Gross Profit	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43	28
Total Revenue	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43	28
Operating Revenue	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43	28
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	31	33	46	44	41	51	49	51	53	53	55
Selling, General & Admin Expense	8.86	9.41	11	11	10	10	12	9.30	11	10	14
Research & Development Expense	22	23	35	33	31	41	37	42	42	43	41
Total Other Income / (Expense), net	-3.87	-0.42	0.15	0.30	0.42	-0.08	-1.74	-6.33	-10	-12	-12
Interest Expense	6.14	4.25	4.34	4.36	4.43	4.96	6.32	11	15	17	18
Interest & Investment Income	2.26	3.84	4.49	4.65	4.85	4.88	4.58	4.62	5.32	5.26	4.41
Other Income / (Expense), net	0.00	-0.00	-0.00	0.00	0.00	-0.00	-0.00	0.00	-0.01	0.02	1.90
Income Tax Expense	-	-	-	0.00	0.00	-	0.00	0.01	0.00	-	0.04
Basic Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)	($1.28)
Weighted Average Basic Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M	30.64M
Diluted Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)	($1.28)
Weighted Average Diluted Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M	30.64M
Weighted Average Basic & Diluted Shares Outstanding	28.43M	27.93M	26.49M	26.55M	26.58M	26.76M	27.32M	27.45M	30.43M	30.67M	29.38M

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	29	-0.45	30	32	57	79	245	-424	-35	87
Net Cash From Operating Activities	-9.69	-9.03	-19	-49	-70	-14	-46	-74	-121	-135
Net Cash From Continuing Operating Activities	-9.69	-9.03	-19	-49	-70	-14	-46	-74	-121	-135
Net Income / (Loss) Continuing Operations	-5.41	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Consolidated Net Income / (Loss)	-5.41	-4.26	-30	-62	-97	-20	-58	-129	-164	-145
Depreciation Expense	0.27	0.23	0.18	0.32	0.51	0.56	0.62	0.68	0.65	0.61
Amortization Expense	-	-	0.01	-1.23	0.89	1.06	1.47	1.66	1.72	1.79
Non-Cash Adjustments To Reconcile Net Income	1.99	2.02	7.59	11	10	12	16	45	35	40
Changes in Operating Assets and Liabilities, net	-6.56	-7.03	2.85	3.46	16	-7.83	-6.61	7.38	5.11	-32
Net Cash From Investing Activities	-0.24	-0.05	-243	-142	131	94	39	-395	145	95
Net Cash From Continuing Investing Activities	-0.24	-0.05	-243	-142	131	94	39	-395	145	95
Purchase of Property, Plant & Equipment	-0.24	-0.05	-0.29	-1.06	-0.81	-0.57	-1.37	-0.36	-0.81	-0.36
Purchase of Investments	0.00	0.00	-291	-348	-252	-195	-119	-803	-304	-380
Sale and/or Maturity of Investments	0.00	0.00	48	206	384	290	159	408	449	476
Net Cash From Financing Activities	39	8.63	292	223	-4.49	-0.88	252	44	-59	127
Net Cash From Continuing Financing Activities	39	8.63	292	223	-4.49	-0.88	252	44	-59	127
Repurchase of Common Equity	-1.45	-1.15	-	-0.18	-	-	0.00	0.00	-50	-0.95
Issuance of Common Equity	0.00	0.00	294	227	3.01	0.50	2.55	12	2.47	6.47
Other Financing Activities, net	0.16	0.03	1.52	2.95	0.00	0.00	250	32	-12	122
Cash Interest Paid	0.33	0.35	1.09	1.04	0.42	0.00	-	0.00	0.00	42

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-13	13	23	-59	-8.91	9.67	18	18	120	-69	-24
Net Cash From Operating Activities	-18	-11	-25	-25	-36	-34	-37	-21	-10	-67	-11
Net Cash From Continuing Operating Activities	-18	-11	-25	-25	-36	-34	-37	-21	-10	-67	-11
Net Income / (Loss) Continuing Operations	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Consolidated Net Income / (Loss)	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22	-39
Depreciation Expense	0.17	0.18	0.17	0.16	0.16	0.17	0.16	0.15	0.14	0.15	0.15
Amortization Expense	-0.37	1.21	0.43	0.42	0.43	0.44	0.44	0.44	0.45	0.46	0.46
Non-Cash Adjustments To Reconcile Net Income	13	8.19	11	8.94	9.16	6.33	13	14	18	-5.28	48
Changes in Operating Assets and Liabilities, net	2.96	6.15	8.19	4.91	-8.92	0.93	-7.16	11	4.32	-40	-20
Net Cash From Investing Activities	-32	21	85	-20	31	49	69	-2.44	59	-29	15
Net Cash From Continuing Investing Activities	-32	21	85	-20	31	49	69	-2.44	59	-29	15
Purchase of Property, Plant & Equipment	-0.05	-0.18	-0.18	-0.19	-0.16	-0.28	-0.03	-0.03	-0.04	-0.26	-0.04
Purchase of Investments	-180	-128	-49	-119	-70	-66	-59	-149	-51	-121	-123
Sale and/or Maturity of Investments	148	149	134	99	101	116	128	147	110	92	137
Net Cash From Financing Activities	37	1.95	-38	-13	-3.07	-5.16	-14	42	71	28	-29
Net Cash From Continuing Financing Activities	37	1.95	-38	-13	-3.07	-5.16	-14	42	71	28	-29
Repurchase of Common Equity	-	-	-38	-12	-	-	0.00	-	-0.37	-0.58	-4.42
Issuance of Common Equity	2.70	3.42	1.27	0.78	0.16	0.26	0.81	0.98	4.13	0.56	0.29
Other Financing Activities, net	35	-1.76	-1.27	-1.80	-3.23	-5.47	-14	41	68	27	-24
Cash Interest Paid	-	-	-	-	-	-	0.00	-	-	-	18
Cash Income Taxes Paid	-	-	-	-	-	-	0.00	-	-	-	0.01

This table presents AnaptysBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	62	329	509	435	417	643	610	452	484
Total Current Assets	58	253	434	378	397	554	447	407	432
Cash & Equivalents	51	81	114	171	250	496	71	36	123
Short-Term Investments	0.00	167	313	203	143	52	370	355	262
Accounts Receivable	1.23	-	-	-	0.00	0.88	1.42	6.85	41
Prepaid Expenses	1.63	2.69	6.96	3.51	2.91	4.90	4.55	9.08	5.74
Plant, Property, & Equipment, net	0.47	0.67	1.45	1.62	1.78	2.28	2.09	2.10	1.85
Total Noncurrent Assets	3.50	76	73	56	18	87	161	43	50
Long-Term Investments	0.00	76	73	54	18	67	143	27	35
Other Noncurrent Operating Assets	3.44	0.05	0.15	1.48	0.60	20	18	16	15
Total Liabilities & Shareholders' Equity	62	329	509	435	417	643	610	452	484
Total Liabilities	23	22	23	30	20	287	348	364	413
Total Current Liabilities	5.71	14	22	30	20	16	26	37	45
Accounts Payable	2.28	2.32	5.44	16	4.22	1.74	2.78	4.70	4.00
Accrued Expenses	3.43	4.88	8.76	11	15	13	22	31	40
Other Current Liabilities	0.00	0.02	0.06	0.87	0.34	1.51	1.64	1.78	1.93
Total Noncurrent Liabilities	17	7.69	0.80	0.65	0.00	271	322	327	368
Other Noncurrent Operating Liabilities	3.24	-	0.80	0.65	0.00	271	322	327	368
Total Equity & Noncontrolling Interests	-38	308	486	405	397	356	262	88	71
Total Preferred & Common Equity	-38	308	486	405	397	356	262	88	71
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-38	308	486	405	397	356	262	88	71
Common Stock	17	393	633	649	661	679	718	703	830
Retained Earnings	-55	-85	-147	-244	-264	-322	-450	-614	-759
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.43	-0.22	0.34	-0.00	-0.42	-5.25	-0.80	0.31

This table presents AnaptysBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	619	552	517	487	406	427	493	422
Total Current Assets	450	437	439	428	372	367	449	363
Cash & Equivalents	59	95	35	26	54	72	192	99
Short-Term Investments	384	337	394	387	301	279	239	241
Accounts Receivable	1.18	1.52	3.18	3.27	7.09	9.01	12	18
Prepaid Expenses	6.30	4.48	5.87	12	11	7.54	6.37	5.29
Plant, Property, & Equipment, net	1.97	1.98	2.02	2.25	1.95	1.83	1.73	1.74
Total Noncurrent Assets	166	113	77	57	31	58	43	57
Long-Term Investments	148	95	59	40	15	43	28	43
Other Noncurrent Operating Assets	19	18	17	17	16	16	15	14
Total Liabilities & Shareholders' Equity	619	552	517	487	406	427	493	422
Total Liabilities	341	361	369	367	358	417	409	388
Total Current Liabilities	21	36	42	39	32	40	44	44
Accounts Payable	3.01	3.17	4.76	6.52	4.58	4.89	3.59	6.12
Accrued Expenses	16	31	35	31	26	34	38	36
Other Current Liabilities	1.60	1.67	1.71	1.74	1.81	1.85	1.89	1.96
Total Noncurrent Liabilities	320	325	327	328	326	377	365	344
Other Noncurrent Operating Liabilities	320	325	327	328	326	377	365	344
Total Equity & Noncontrolling Interests	278	191	148	120	48	9.88	84	34
Total Preferred & Common Equity	278	191	148	120	48	9.88	84	34
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	278	191	148	120	48	9.88	84	34
Common Stock	708	689	687	695	706	715	821	833
Retained Earnings	-424	-495	-535	-572	-658	-705	-738	-799
Accumulated Other Comprehensive Income / (Loss)	-6.01	-3.27	-3.61	-2.35	-0.62	-0.42	0.76	0.16

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-5.05%	-40.06%	-50.00%	60.00%	837.50%	-15.77%	-83.72%	66.78%	432.03%
EBITDA Growth	0.00%	18.79%	-704.44%	-128.10%	-56.38%	78.99%	-145.53%	-106.28%	-43.64%	30.55%
EBIT Growth	0.00%	18.57%	-661.66%	-123.55%	-60.63%	77.76%	-137.66%	-102.80%	-42.79%	30.09%
NOPAT Growth	0.00%	8.94%	-851.44%	-131.83%	-61.01%	77.77%	-137.92%	-102.69%	-42.77%	30.08%
Net Income Growth	0.00%	21.20%	-606.03%	-105.04%	-57.87%	79.52%	-189.98%	-122.72%	-27.11%	11.24%
EPS Growth	0.00%	23.58%	6.17%	-64.47%	-44.00%	79.72%	-189.04%	-116.59%	-33.04%	15.79%
Operating Cash Flow Growth	0.00%	6.85%	-115.26%	-149.54%	-43.32%	79.64%	-224.36%	-60.26%	-64.15%	-12.03%
Free Cash Flow Firm Growth	0.00%	0.00%	-310.17%	-166.95%	-38.84%	58.88%	938.11%	-108.46%	-520.40%	43.80%
Invested Capital Growth	0.00%	0.00%	-231.93%	-168.83%	-250.80%	34.59%	-1,681.15%	-24.47%	-2.41%	-6.11%
Revenue Q/Q Growth	0.00%	0.00%	2.52%	-37.50%	60.00%	316.67%	-48.29%	129.11%	14.69%	59.66%
EBITDA Q/Q Growth	0.00%	0.00%	-9.88%	-25.01%	-1.71%	71.80%	-648.13%	5.20%	-11.68%	22.40%
EBIT Q/Q Growth	0.00%	0.00%	-9.81%	-22.73%	-2.59%	69.96%	-842.28%	4.30%	-10.90%	22.04%
NOPAT Q/Q Growth	0.00%	0.00%	-16.03%	-23.08%	-2.48%	69.96%	-617.30%	4.31%	-10.90%	22.02%
Net Income Q/Q Growth	0.00%	0.00%	-8.22%	-19.67%	-3.48%	73.01%	-789.03%	4.54%	-10.69%	12.33%
EPS Q/Q Growth	0.00%	0.00%	32.14%	-21.95%	-2.86%	72.96%	-780.65%	5.38%	-12.18%	15.79%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	3.76%	-18.23%	-5.33%	79.04%	-370.77%	16.57%	-24.36%	-31.38%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-18.04%	-6.36%	60.53%	22,971.16%	-107.76%	-28.14%	3.33%
Invested Capital Q/Q Growth	0.00%	0.00%	-103.54%	-118.01%	-8.28%	-1.31%	-4,394.03%	-2.95%	0.91%	6.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-25.89%	-22.15%	-297.24%	-1,355.98%	-1,325.30%	-29.70%	-86.56%	-1,096.60%	-944.44%	-123.29%
Operating Margin	-18.91%	-18.13%	-287.81%	-1,334.44%	-1,342.90%	-31.84%	-89.93%	-1,119.41%	-958.27%	-125.93%
EBIT Margin	-27.45%	-23.54%	-299.18%	-1,337.62%	-1,342.89%	-31.85%	-89.87%	-1,119.30%	-958.29%	-125.91%
Profit (Net Income) Margin	-30.76%	-25.53%	-300.70%	-1,233.12%	-1,216.70%	-26.57%	-91.49%	-1,251.33%	-953.66%	-159.11%
Tax Burden Percent	102.64%	100.00%	100.00%	99.69%	99.84%	100.00%	100.00%	100.02%	100.00%	100.00%
Interest Burden Percent	109.16%	108.43%	100.51%	92.47%	90.74%	83.43%	101.79%	111.78%	99.52%	126.36%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-237.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-225.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	215.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-21.69%	-17.34%	-15.53%	-21.84%	-4.97%	-15.35%	-41.62%	-93.44%	-182.71%
Cash Return on Invested Capital (CROIC)	0.00%	-437.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-6.32%	-15.28%	-15.96%	-22.76%	-5.61%	-10.72%	-18.37%	-30.94%	-24.55%
Return on Assets (ROA)	0.00%	-6.85%	-15.36%	-14.71%	-20.62%	-4.68%	-10.91%	-20.54%	-30.79%	-31.02%
Return on Common Equity (ROCE)	0.00%	21.13%	-13.46%	-15.53%	-21.84%	-4.97%	-15.35%	-41.62%	-93.44%	-182.71%
Return on Equity Simple (ROE_SIMPLE)	0.00%	11.14%	-9.78%	-12.68%	-24.03%	-5.02%	-16.22%	-49.11%	-185.71%	-204.93%
Net Operating Profit after Tax (NOPAT)	-2.33	-2.12	-20	-47	-75	-17	-40	-81	-115	-80
NOPAT Margin	-13.23%	-12.69%	-201.47%	-934.11%	-940.03%	-22.29%	-62.95%	-783.59%	-670.79%	-88.15%
Net Nonoperating Expense Percent (NNEP)	0.00%	-11.43%	-5.71%	-3.73%	-4.81%	-0.77%	-3.51%	-8.02%	-9.69%	-15.44%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-30.75%	-130.63%	-113.54%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	20.43%	25.71%	93.38%	310.52%	201.18%	25.14%	34.02%	356.21%	244.48%	46.44%
R&D to Revenue	98.48%	92.42%	294.43%	1,123.92%	1,241.73%	106.70%	155.91%	863.21%	813.79%	179.49%
Operating Expenses to Revenue	118.91%	118.13%	387.81%	1,434.44%	1,442.90%	131.84%	189.93%	1,219.41%	1,058.27%	225.93%
Earnings before Interest and Taxes (EBIT)	-4.82	-3.93	-30	-67	-107	-24	-57	-115	-164	-115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.55	-3.70	-30	-68	-106	-22	-55	-113	-162	-113
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	7.69	3.51	1.09	1.48	2.68	3.36	6.46	5.68
Price to Tangible Book Value (P/TBV)	0.00	0.00	7.69	3.51	1.09	1.48	2.68	3.36	6.46	5.68
Price to Revenue (P/Rev)	0.00	0.00	236.67	341.30	55.11	7.84	15.13	85.65	33.18	4.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	205.68	242.77	1.72	2.36	5.39	28.86	8.82	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	1.67	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.35	0.05	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.35	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.95	-1.00	-1.01	-1.03	-1.05	-1.36	-1.94	-2.86	-5.28
Leverage Ratio	0.00	1.58	1.13	1.06	1.06	1.06	1.41	2.03	3.03	5.89
Compound Leverage Factor	0.00	1.72	1.13	0.98	0.96	0.89	1.43	2.27	3.02	7.44
Debt to Total Capital	0.00%	26.02%	4.48%	1.53%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	2.14%	1.53%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	26.02%	2.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	146.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-72.06%	95.52%	98.47%	99.66%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-3.74	-0.49	-0.11	-0.01	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	10.13	10.43	7.27	4.03	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-3.74	-0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-6.52	-0.72	-0.16	-0.02	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	17.67	15.38	10.55	5.68	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-6.52	-0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	65.43	45.39	8.14	17.99	2.11	0.71	-1.14	-1.25
Noncontrolling Interest Sharing Ratio	0.00%	197.40%	22.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	10.20	17.93	19.89	12.79	20.01	34.40	17.16	10.87	9.51
Quick Ratio	0.00	9.19	17.63	19.56	12.67	19.86	34.10	16.99	10.62	9.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-3.90	-16	-43	-59	-24	204	-17	-107	-60
Operating Cash Flow to CapEx	-4,073.11%	-18,060.00%	-6,702.76%	-4,563.12%	-8,635.65%	-2,488.05%	-3,398.96%	-20,556.70%	-14,969.02%	-37,803.63%
Free Cash Flow to Firm to Interest Expense	0.00	-8.52	-9.02	-25.87	-56.99	0.00	141.01	-0.82	-5.94	-1.20
Operating Cash Flow to Interest Expense	-21.07	-19.72	-10.95	-29.36	-66.78	0.00	-31.67	-3.49	-6.68	-2.70
Operating Cash Flow Less CapEx to Interest Expense	-21.59	-19.83	-11.11	-30.01	-67.55	0.00	-32.60	-3.50	-6.72	-2.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.27	0.05	0.01	0.02	0.18	0.12	0.02	0.03	0.20
Accounts Receivable Turnover	0.00	13.62	0.00	0.00	0.00	0.00	0.00	8.96	4.15	3.83
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	35.42	17.61	4.74	5.22	44.10	31.07	4.71	8.20	46.25
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	26.80	0.00	0.00	0.00	0.00	0.00	40.72	87.97	95.20
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	26.80	0.00	0.00	0.00	0.00	0.00	40.72	87.97	95.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1.79	-2.36	-6.33	-22	-15	-259	-322	-330	-350
Invested Capital Turnover	0.00	18.69	-35.09	-1.15	-0.56	-4.08	-0.46	-0.04	-0.05	-0.27
Increase / (Decrease) in Invested Capital	0.00	1.79	-4.14	-3.98	-16	7.68	-244	-63	-7.75	-20
Enterprise Value (EV)	0.00	0.00	2,057	1,214	14	177	341	297	151	-18
Market Capitalization	0.00	0.00	2,367	1,706	441	588	956	881	569	403
Book Value per Share	$0.00	($14.50)	$13.09	$18.18	$14.93	$14.51	$12.96	$9.22	$3.32	$2.33
Tangible Book Value per Share	$0.00	($14.50)	$13.09	$18.18	$14.93	$14.51	$12.96	$9.22	$3.32	$2.33
Total Capital	0.00	53	322	494	406	397	356	262	88	71
Total Debt	0.00	14	14	7.57	1.38	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	14	7.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-37	-310	-493	-427	-411	-615	-584	-418	-421
Capital Expenditures (CapEx)	0.24	0.05	0.29	1.06	0.81	0.57	1.35	0.36	0.81	0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	1.27	-2.93	-7.13	-25	-17	-10	-20	-22	1.08
Debt-free Net Working Capital (DFNWC)	0.00	53	245	420	350	377	538	421	369	386
Net Working Capital (NWC)	0.00	53	239	412	348	377	538	421	369	386
Net Nonoperating Expense (NNE)	3.08	2.14	9.92	15	22	3.22	18	48	49	65
Net Nonoperating Obligations (NNO)	0.00	-37	-310	-493	-427	-411	-615	-584	-418	-421
Total Depreciation and Amortization (D&A)	0.27	0.23	0.19	-0.92	1.41	1.62	2.09	2.34	2.38	2.40
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	7.60%	-29.26%	-142.56%	-308.18%	-22.55%	-16.34%	-195.30%	-125.38%	1.18%
Debt-free Net Working Capital to Revenue	0.00%	314.67%	2,454.81%	8,399.08%	4,369.66%	502.32%	851.25%	4,094.01%	2,153.02%	423.37%
Net Working Capital to Revenue	0.00%	314.67%	2,386.06%	8,247.60%	4,352.48%	502.32%	851.25%	4,094.01%	2,153.02%	423.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.12)	($1.62)	($1.52)	($2.50)	($3.60)	($0.73)	($2.11)	($4.57)	($6.08)	($5.12)
Adjusted Weighted Average Basic Shares Outstanding	2.55M	2.64M	23.81M	26.99M	27.27M	27.37M	27.43M	28.17M	26.92M	28.38M
Adjusted Diluted Earnings per Share	($2.12)	($1.62)	($1.52)	($2.50)	($3.60)	($0.73)	($2.11)	($4.57)	($6.08)	($5.12)
Adjusted Weighted Average Diluted Shares Outstanding	2.55M	2.64M	23.81M	26.99M	27.27M	27.37M	27.43M	28.17M	26.92M	28.38M
Adjusted Basic & Diluted Earnings per Share	($2.12)	($1.62)	($1.52)	($2.50)	($3.60)	($0.73)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.55M	2.64M	19.78M	24.67M	27.06M	27.30M	27.67M	27.93M	26.76M	30.67M
Normalized Net Operating Profit after Tax (NOPAT)	-2.33	-2.12	-20	-47	-75	-17	-40	-81	-115	-80
Normalized NOPAT Margin	-13.23%	-12.69%	-201.47%	-934.11%	-940.03%	-22.29%	-62.95%	-783.59%	-670.79%	-88.15%
Pre Tax Income Margin	-29.97%	-25.53%	-300.70%	-1,236.96%	-1,218.60%	-26.57%	-91.49%	-1,251.09%	-953.68%	-159.10%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.49	-8.58	-16.86	-40.48	-103.20	0.00	-39.16	-5.45	-9.09	-2.29
NOPAT to Interest Expense	-5.06	-4.62	-11.35	-28.27	-72.24	0.00	-27.43	-3.82	-6.36	-1.61
EBIT Less CapEx to Interest Expense	-11.00	-8.69	-17.02	-41.13	-103.97	0.00	-40.09	-5.47	-9.14	-2.30
NOPAT Less CapEx to Interest Expense	-5.57	-4.73	-11.51	-28.92	-73.01	0.00	-28.36	-3.84	-6.41	-1.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-26.73%	-26.95%	0.00%	-0.30%	0.00%	0.00%	0.00%	0.00%	-30.56%	-0.65%

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-93.81%	573.39%	41.65%	184.54%	156.61%	32.27%	422.49%	217.08%	804.67%	378.77%	286.84%
EBITDA Growth	-392.13%	20.10%	-41.29%	-44.44%	-24.51%	-68.92%	5.05%	-0.44%	40.32%	78.21%	39.83%
EBIT Growth	-340.25%	16.62%	-39.89%	-44.42%	-27.34%	-62.21%	4.96%	-0.45%	39.67%	77.10%	39.25%
NOPAT Growth	-338.16%	16.64%	-39.85%	-44.40%	-27.33%	-62.23%	4.95%	-0.44%	39.69%	77.05%	34.74%
Net Income Growth	-402.58%	18.82%	-22.07%	-22.40%	-11.36%	-59.81%	0.72%	-17.10%	11.95%	48.39%	10.49%
EPS Growth	-391.67%	21.85%	-20.61%	-30.43%	-19.49%	-70.97%	-3.80%	-14.00%	19.15%	60.38%	21.95%
Operating Cash Flow Growth	-153.31%	57.77%	-16.91%	-5.23%	-105.52%	-221.47%	-51.63%	16.08%	72.34%	-94.10%	71.28%
Free Cash Flow Firm Growth	2,250.46%	-79.71%	-84.12%	-81.34%	-102.24%	-148.18%	-211.44%	-66.01%	488.34%	161.54%	117.31%
Invested Capital Growth	-5,333.45%	-24.47%	-25.90%	-27.05%	-6.40%	-2.41%	3.77%	-12.72%	-12.26%	-6.11%	-8.24%
Revenue Q/Q Growth	6.33%	426.53%	-79.82%	151.82%	-4.10%	171.40%	-20.28%	52.82%	173.60%	43.63%	-35.59%
EBITDA Q/Q Growth	-8.93%	17.57%	-78.19%	9.72%	6.10%	-11.83%	-21.75%	4.50%	44.20%	59.18%	-176.65%
EBIT Q/Q Growth	-6.61%	12.33%	-70.94%	9.60%	6.00%	-11.68%	-0.16%	4.46%	43.55%	57.61%	-165.70%
NOPAT Q/Q Growth	-6.60%	12.35%	-70.95%	9.59%	6.01%	-11.67%	-0.16%	4.45%	43.56%	57.51%	-184.79%
Net Income Q/Q Growth	-2.91%	21.16%	-67.55%	9.97%	6.37%	-13.14%	-4.09%	-6.20%	29.59%	33.69%	-80.54%
EPS Q/Q Growth	-2.61%	21.19%	-69.89%	5.06%	6.00%	-12.77%	-3.14%	-4.27%	33.33%	44.74%	-103.17%
Operating Cash Flow Q/Q Growth	26.50%	39.79%	-129.93%	-3.42%	-43.55%	5.83%	-8.45%	42.76%	52.68%	-560.77%	83.95%
Free Cash Flow Firm Q/Q Growth	20.47%	-84.24%	-16.15%	17.20%	-114.44%	-239.51%	-93.96%	135.74%	65.00%	-46.20%	-45.45%
Invested Capital Q/Q Growth	-16.81%	-2.95%	-4.01%	-1.58%	2.18%	0.91%	2.26%	-18.99%	2.58%	6.34%	0.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-2,306.88%	-361.15%	-3,188.65%	-1,143.15%	-1,119.32%	-461.22%	-579.44%	-362.10%	-73.84%	-20.99%	-90.13%
Operating Margin	-2,291.80%	-381.51%	-3,231.51%	-1,160.20%	-1,137.19%	-467.91%	-587.84%	-367.52%	-75.81%	-22.43%	-99.16%
EBIT Margin	-2,291.49%	-381.57%	-3,231.80%	-1,160.12%	-1,137.16%	-467.93%	-587.87%	-367.52%	-75.83%	-22.38%	-92.32%
Profit (Net Income) Margin	-2,591.03%	-387.97%	-3,220.89%	-1,151.59%	-1,124.41%	-468.75%	-612.01%	-425.30%	-109.44%	-50.53%	-141.62%
Tax Burden Percent	100.00%	100.09%	100.00%	100.00%	100.00%	99.99%	100.00%	100.02%	100.00%	99.97%	100.11%
Interest Burden Percent	113.07%	101.59%	99.66%	99.27%	98.88%	100.19%	104.11%	115.70%	144.32%	225.83%	153.24%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.79%	-41.62%	-52.40%	-63.62%	-74.28%	-93.44%	-136.73%	-214.89%	-161.81%	-182.71%	-343.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-19.73%	-6.26%	-58.71%	-26.77%	-30.77%	-15.11%	-28.19%	-23.72%	-8.84%	-4.36%	-24.95%
Return on Assets (ROA)	-22.31%	-6.37%	-58.51%	-26.58%	-30.42%	-15.13%	-29.35%	-27.44%	-12.76%	-9.85%	-38.27%
Return on Common Equity (ROCE)	-40.79%	-41.62%	-52.40%	-63.62%	-74.28%	-93.44%	-136.73%	-214.89%	-161.81%	-182.71%	-343.83%
Return on Equity Simple (ROE_SIMPLE)	-48.57%	0.00%	-71.55%	-97.01%	-122.79%	0.00%	-341.79%	-1,721.99%	-196.35%	0.00%	-413.34%
Net Operating Profit after Tax (NOPAT)	-21	-18	-31	-28	-26	-29	-30	-28	-16	-6.77	-19
NOPAT Margin	-1,604.26%	-267.05%	-2,262.06%	-812.14%	-796.03%	-327.53%	-411.49%	-257.27%	-53.07%	-15.70%	-69.42%
Net Nonoperating Expense Percent (NNEP)	-2.60%	-1.37%	-2.35%	-2.21%	-2.09%	-2.54%	-3.21%	-4.18%	-3.71%	-3.58%	-5.33%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.94%	-	-	-	-33.48%	-	-	-	-9.55%	-56.66%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	685.38%	138.18%	787.34%	308.67%	306.57%	114.11%	171.86%	84.72%	35.19%	23.64%	50.88%
R&D to Revenue	1,706.42%	343.33%	2,544.18%	951.53%	930.62%	453.79%	515.98%	382.80%	140.63%	98.78%	148.28%
Operating Expenses to Revenue	2,391.80%	481.51%	3,331.51%	1,260.20%	1,237.19%	567.91%	687.84%	467.52%	175.81%	122.43%	199.16%
Earnings before Interest and Taxes (EBIT)	-30	-26	-44	-40	-38	-42	-42	-40	-23	-9.65	-26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-25	-44	-40	-37	-42	-42	-40	-22	-9.05	-25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.59	3.36	3.18	3.63	3.96	6.46	12.61	69.30	10.90	5.68	16.76
Price to Tangible Book Value (P/TBV)	2.59	3.36	3.18	3.63	3.96	6.46	12.61	69.30	10.90	5.68	16.76
Price to Revenue (P/Rev)	160.44	85.65	56.85	41.65	31.87	33.18	26.25	22.47	16.08	4.41	5.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	28.93	28.86	7.64	3.87	1.57	8.82	10.13	9.55	8.07	0.00	1.67
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.48	-1.94	-2.15	-2.34	-2.62	-2.86	-3.75	-5.57	-4.45	-5.28	-9.21
Leverage Ratio	1.58	2.03	2.26	2.48	2.78	3.03	4.01	5.97	4.79	5.89	10.12
Compound Leverage Factor	1.78	2.06	2.25	2.46	2.75	3.04	4.17	6.90	6.91	13.30	15.51
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.99	1.19	0.38	0.12	-0.13	-0.25	-0.54	-0.65	0.20	-0.53	-0.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	21.39	17.16	12.21	10.53	10.92	10.87	11.53	9.09	10.23	9.51	8.25
Quick Ratio	21.09	16.99	12.09	10.39	10.63	10.62	11.20	8.90	10.08	9.38	8.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	286	45	38	44	-6.40	-22	-42	15	25	13	7.30
Operating Cash Flow to CapEx	-35,494.00%	-6,105.71%	-14,038.86%	-13,373.16%	-22,514.81%	-12,267.50%	-137,974.07%	-64,612.12%	-28,828.57%	-25,350.57%	-30,571.43%
Free Cash Flow to Firm to Interest Expense	46.68	10.62	8.73	10.18	-1.45	-4.38	-6.68	1.38	1.61	0.77	0.40
Operating Cash Flow to Interest Expense	-2.89	-2.51	-5.67	-5.83	-8.23	-6.93	-5.90	-1.95	-0.65	-3.83	-0.59
Operating Cash Flow Less CapEx to Interest Expense	-2.90	-2.55	-5.71	-5.87	-8.27	-6.98	-5.90	-1.95	-0.66	-3.85	-0.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.02	0.02	0.02	0.03	0.03	0.05	0.06	0.12	0.20	0.27
Accounts Receivable Turnover	4.63	8.96	8.75	6.14	6.73	4.15	5.33	5.00	7.39	3.83	8.96
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.05	4.71	5.16	6.34	7.08	8.20	11.67	15.81	28.72	46.25	60.55
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	78.89	40.72	41.72	59.47	54.27	87.97	68.45	73.00	49.36	95.20	40.74
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	78.89	40.72	41.72	59.47	54.27	87.97	68.45	73.00	49.36	95.20	40.74
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-313	-322	-335	-340	-333	-330	-322	-384	-374	-350	-349
Invested Capital Turnover	-0.03	-0.04	-0.04	-0.04	-0.05	-0.05	-0.07	-0.08	-0.16	-0.27	-0.33
Increase / (Decrease) in Invested Capital	-307	-63	-69	-72	-20	-7.75	13	-43	-41	-20	-27
Enterprise Value (EV)	130	297	82	50	24	151	233	291	462	-18	187
Market Capitalization	720	881	608	539	477	569	603	685	920	403	570
Book Value per Share	$9.83	$9.22	$6.84	$5.60	$4.54	$3.32	$1.79	$0.36	$3.07	$2.33	$1.11
Tangible Book Value per Share	$9.83	$9.22	$6.84	$5.60	$4.54	$3.32	$1.79	$0.36	$3.07	$2.33	$1.11
Total Capital	278	262	191	148	120	88	48	9.88	84	71	34
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-590	-584	-526	-489	-453	-418	-370	-393	-458	-421	-383
Capital Expenditures (CapEx)	0.05	0.18	0.18	0.19	0.16	0.28	0.03	0.03	0.04	0.26	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-20	-30	-33	-24	-22	-15	-24	-25	1.08	-21
Debt-free Net Working Capital (DFNWC)	429	421	401	397	389	369	340	327	405	386	319
Net Working Capital (NWC)	429	421	401	397	389	369	340	327	405	386	319
Net Nonoperating Expense (NNE)	13	8.23	13	12	11	13	14	18	17	15	20
Net Nonoperating Obligations (NNO)	-590	-584	-526	-489	-453	-418	-370	-393	-458	-421	-383
Total Depreciation and Amortization (D&A)	-0.20	1.39	0.59	0.59	0.59	0.60	0.61	0.60	0.60	0.60	0.61
Debt-free, Cash-free Net Working Capital to Revenue	-302.56%	-195.30%	-278.66%	-251.89%	-161.93%	-125.38%	-63.34%	-78.34%	-44.28%	1.18%	-18.65%
Debt-free Net Working Capital to Revenue	9,563.05%	4,094.01%	3,754.18%	3,068.45%	2,599.08%	2,153.02%	1,481.24%	1,072.85%	708.04%	423.37%	285.21%
Net Working Capital to Revenue	9,563.05%	4,094.01%	3,754.18%	3,068.45%	2,599.08%	2,153.02%	1,481.24%	1,072.85%	708.04%	423.37%	285.21%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)	($1.28)
Adjusted Weighted Average Basic Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M	30.64M
Adjusted Diluted Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)	($1.28)
Adjusted Weighted Average Diluted Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M	30.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.43M	27.93M	26.49M	26.55M	26.58M	26.76M	27.32M	27.45M	30.43M	30.67M	29.38M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-18	-31	-28	-26	-29	-30	-28	-16	-6.77	-19
Normalized NOPAT Margin	-1,604.26%	-267.05%	-2,262.06%	-812.14%	-796.03%	-327.53%	-411.49%	-257.27%	-53.07%	-15.70%	-69.42%
Pre Tax Income Margin	-2,591.03%	-387.62%	-3,220.89%	-1,151.59%	-1,124.41%	-468.80%	-612.01%	-425.22%	-109.44%	-50.54%	-141.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.83	-6.11	-10.24	-9.21	-8.52	-8.50	-6.68	-3.68	-1.48	-0.55	-1.42
NOPAT to Interest Expense	-3.38	-4.28	-7.17	-6.45	-5.96	-5.95	-4.68	-2.58	-1.03	-0.39	-1.07
EBIT Less CapEx to Interest Expense	-4.84	-6.15	-10.28	-9.25	-8.55	-8.56	-6.69	-3.68	-1.48	-0.57	-1.42
NOPAT Less CapEx to Interest Expense	-3.39	-4.32	-7.21	-6.49	-6.00	-6.01	-4.68	-2.58	-1.04	-0.40	-1.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-27.45%	-34.72%	-33.82%	-30.56%	-7.64%	0.00%	-0.22%	-0.65%	-3.82%

Key Financial Trends

ANAPTSYSBIO, INC. (NASDAQ: ANAB) has reported its Q1 2025 financial results showing continued operational and financial trends from the previous quarters and years.

Key Positives:

The company generated $27.8 million in operating revenue in Q1 2025, showing an increase compared to earlier quarters, suggesting growth in product or service sales.
Net cash from continuing investing activities was positive $14.8 million in Q1 2025, helped by maturity/sale of investments exceeding purchases, indicating effective management of investment portfolio.
Cash and equivalents remain substantial at $98.6 million by the end of Q1 2025, providing liquidity for operations and investment.
Weighted average shares outstanding have increased over the years from approximately 26.5 million in Q3 2023 to 30.6 million in Q1 2025, which may reflect capital raising efforts to support growth.
Total assets decreased from $618.5 million in Q3 2022 to $422.1 million in Q1 2025, mainly due to declining long-term investments, which conserves capital efficiency.

Neutral Observations:

Gross profit remains strong relative to revenue, with $27.8 million gross profit in Q1 2025 and zero cost of revenue, indicating minimal direct sales costs.
The company maintains significant investment in Research & Development, with expenses around $41.2 million in Q1 2025, consistent with past quarters, emphasizing its focus on drug development.
Selling, General & Administrative expenses of about $14.1 million in Q1 2025 continue to be a significant part of operating expenses, in line with historical levels.
Total liabilities remain high relative to equity, with total liabilities at $388 million and equity at $34 million as of Q1 2025, typical for a biotech focused on long-term investments and R&D funding.

Key Negatives:

The company reported a net loss of $39.3 million in Q1 2025, an increase from prior quarters' losses, reflecting high costs and interest expenses surpassing income.
Interest expense is significant, at $18.1 million cash paid in Q1 2025 and $18.1 million recognized interest expense, indicating heavy debt or financing costs weighing on profitability.
Net cash used in operating activities was $10.7 million in Q1 2025, consistent with sustained negative cash flow from operations over prior periods, requiring ongoing financing.
The company repurchased $4.4 million in common equity in Q1 2025 despite ongoing losses and cash flow pressures, which could constrain liquidity.
Total equity has declined from a peak of approximately $277 million in Q3 2022 down to $34 million by Q1 2025, reflecting cumulative losses and balance sheet erosion over time.

Summary:

AnaptysBio continues to invest heavily in R&D and managing a large portfolio of investments to fund its operations. Revenue growth is positive, but losses are increasing, largely due to high interest expenses and sustained operating costs.

Liquidity remains adequate, with substantial cash, cash equivalents, and investments, although equity base has eroded, primarily due to ongoing net losses.

The company's ability to reduce losses, manage interest costs, and convert R&D into profitable products will be critical moving forward. Investors should monitor cash flow from operations and financing strategies, as well as progress in drug development and market opportunity realization to assess potential for future profitability.

08/04/25 03:45 AMAI Generated. May Contain Errors.

Frequently Asked Questions About AnaptysBio's Financials

When does AnaptysBio's financial year end?

According to the most recent income statement we have on file, AnaptysBio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AnaptysBio's net income changed over the last 9 years?

AnaptysBio's net income appears to be on an upward trend, with a most recent value of -$145.23 million in 2024, rising from -$5.41 million in 2015. The previous period was -$163.62 million in 2023. Find out what analysts predict for AnaptysBio in the coming months.

What is AnaptysBio's operating income?

AnaptysBio's total operating income in 2024 was -$114.95 million, based on the following breakdown:

Total Gross Profit: $91.28 million
Total Operating Expenses: $206.23 million

How has AnaptysBio's revenue changed over the last 9 years?

Over the last 9 years, AnaptysBio's total revenue changed from $17.57 million in 2015 to $91.28 million in 2024, a change of 419.5%.

How much debt does AnaptysBio have?

AnaptysBio's total liabilities were at $412.97 million at the end of 2024, a 13.4% increase from 2023, and a 1,702.4% increase since 2016.

How much cash does AnaptysBio have?

In the past 8 years, AnaptysBio's cash and equivalents has ranged from $35.97 million in 2023 to $495.73 million in 2021, and is currently $123.08 million as of their latest financial filing in 2024.

How has AnaptysBio's book value per share changed over the last 9 years?

Over the last 9 years, AnaptysBio's book value per share changed from 0.00 in 2015 to 2.33 in 2024, a change of 232.9%.

Related Companies

This page (NASDAQ:ANAB) was last updated on 8/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Financials

Key Financial Trends

Frequently Asked Questions About AnaptysBio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Financials

Annual Income Statements for AnaptysBio

Quarterly Income Statements for AnaptysBio

Annual Cash Flow Statements for AnaptysBio

Quarterly Cash Flow Statements for AnaptysBio

Annual Balance Sheets for AnaptysBio

Quarterly Balance Sheets for AnaptysBio

Annual Metrics And Ratios for AnaptysBio

Quarterly Metrics And Ratios for AnaptysBio

Key Financial Trends

Frequently Asked Questions About AnaptysBio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools